Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02253992
Title Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

B-cell lymphoma

Advanced Solid Tumor

Therapies

Nivolumab + Urelumab

Age Groups: adult
Covered Countries USA | FRA | ESP | DEU

Facility Status City State Zip Country Details
Stanford University School Of Medicine Palo Alto California 94304 United States Details
H. Lee Moffitt Cancer Center Tampa Florida 33612 United States Details
University Of Chicago Chicago Illinois 60637 United States Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Lutherville Maryland 21093 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
NYU Langone Medical Center New York New York 10016 United States Details
Memorial Sloan Kettering Nassau New York New York 10065 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
UPMC Cancer Center Pittsburgh Pennsylvania 15213 United States Details
Md Anderson Houston Texas 77030 United States Details
Local Institution Besancon 25000 France Details
Local Institution Marseille 13005 France Details
Local Institution Rennes Cedex 9 35033 France Details
Local Institution Villejuif 94805 France Details
Universitaetsklinikum Essen Essen 45147 Germany Details
Clinica Universidad de Navarra Pamplona 31008 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field